cannabisnews.com: N.J. AG Asks if MMJ Program Could Violate U.S. Law
function share_this(num) {
tit=encodeURIComponent('N.J. AG Asks if MMJ Program Could Violate U.S. Law');
url=encodeURIComponent('http://www.cannabisnews.com/news/26/thread26483.shtml');
site = new Array(5);
site[0]='http://www.facebook.com/sharer.php?u='+url+'&title='+tit;
site[1]='http://www.stumbleupon.com/submit.php?url='+url+'&title='+tit;
site[2]='http://digg.com/submit?topic=political_opinion&media=video&url='+url+'&title='+tit;
site[3]='http://reddit.com/submit?url='+url+'&title='+tit;
site[4]='http://del.icio.us/post?v=4&noui&jump=close&url='+url+'&title='+tit;
window.open(site[num],'sharer','toolbar=0,status=0,width=620,height=500');
return false;
}
N.J. AG Asks if MMJ Program Could Violate U.S. Law
Posted by CN Staff on April 19, 2011 at 19:21:00 PT
By Susan K. Livio, Statehouse Bureau
Source: Star-Ledger
Trenton -- The debate over the legality of medical marijuana in two western states has prompted State Attorney General Paula Dow to ask the Obama administration whether New Jersey’s future program could violate federal law. Dow’s office sent a letter late today to U.S. Attorney General Eric Holder asking him to clarify whether those licensed to grow or sell pot — as well as the state workers who will administer the program when it launches later this year — could face arrest.
Possession and distribution of the drug is a crime even though 15 states passed laws making it available to select patients."As the state’s chief legal adviser to all of the departments in the Executive Branch, many of which are participating in carrying out the medical marijuana legislation, it is critical that I properly advise them as to the potential criminal and civil ramifications of their actions in carrying out their duties," according to Dow’s letter."Accordingly, I ask that you provide me with clear guidance as to the enforcement position of the Department of Justice relative to New Jersey’s medical marijuana legislation and the scope of the entities and individuals who may be subject to civil suit or criminal prosecution," the letter said.Gov. Chris Christie’s administration raised the question following the public debate last week in Washington state, where Gov. Christine Gregoire, who is weighing whether to sign a law creating a program licensing growers and sellers, asked federal officials if it would run afoul of federal statutes. The Justice Department replied by repeating earlier assertions by Holder that patients legally using a program would not be targeted, but offered no blanket immunity to program operators. Snipped Complete Article: http://drugsense.org/url/GysYttnnSource: Star-Ledger (Newark, NJ)Author: Susan K. Livio, Statehouse BureauPublished: April 19, 2011Copyright: 2011 Newark Morning Ledger Co.Contact: eletters starledger.comWebsite: http://www.nj.com/starledger/CannabisNews Medical Marijuana Archiveshttp://cannabisnews.com/news/list/medical.shtml
Home Comment Email Register Recent Comments Help
Comment #2 posted by Garry Minor on April 20, 2011 at 04:37:35 PT
US Patent for Sativex
RNS Number : 2103F
GW Pharmaceuticals PLC
20 April 2011
US PATENT GRANTED FOR SATIVEX® IN CANCER PAIN
Porton Down, UK; 20 April 2011:
GW Pharmaceuticals plc (AIM: GWP) today announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent which protects the use of Sativex® as a treatment for cancer pain.
The patent, entitled "Pharmaceutical Compositions for the Treatment of Pain", provides an exclusivity period until April 2025. The patent specifically covers a method of treating cancer related pain by administering a combination of the cannabinoids cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC), the two principal cannabinoids in Sativex®. In addition to this newly granted patent, Sativex® is protected by a number of other patents related to different aspects of the product.
Sativex® is currently in Phase III clinical development as a treatment for cancer pain. Cancer pain represents the lead indication for Sativex® in the United States, where the medicine is partnered with Otsuka Pharmaceutical Co. Ltd.
Dr Geoffrey Guy, GW's Chairman, said, "The grant of this US patent covering Sativex® as a treatment for cancer pain is part of a broad platform of intellectual property rights which continue to be developed by GW. GW now has 35 patent families as well as other forms of protection such as plant variety rights and proprietary know-how. We believe that this matrix of intellectual property provides GW with a unique position to benefit from the rich promise within the field of cannabinoid therapeutics."
Sativex® is approved in the UK, Spain, Czech Republic, Canada and New Zealand as a treatment of Multiple Sclerosis spasticity.
[ Post Comment ]
Comment #1 posted by FoM on April 19, 2011 at 19:21:55 PT
Federal Law
It's time to change the Federal Law.
[ Post Comment ]
Post Comment